Department of Cardiovascular, Endocrine-metabolic Diseases and Aging, Istituto Superiore di Sanità, Rome, Italy.
Service of Statistics, Istituto Superiore di Sanità, Rome, Italy.
Bone. 2021 Jan;142:115752. doi: 10.1016/j.bone.2020.115752. Epub 2020 Nov 12.
Osteoporosis-related fractures are a growing public health concern worldwide due to high societal and economic burden. The study aims to assess trends in incidence rates of hip and distal femoral fractures and in the use of anti-osteoporosis drugs in Italy between 2007 and 2017. Patients with hip and distal femoral fractures (ICD-9-CM codes 820.x and 821.x) were identified in the Italian National Hospital Discharge Database while anti-osteoporosis medication data were retrieved from the National Observatory on the Use of Medicines Database. A joinpoint regression analysis was performed to identify the years where the trends in incidence rates of hip and distal femoral fractures changed significantly; the average annual percentage change for the period of observation was estimated. Hospitalizations for femoral fractures were 991,059, of which 91.4% were hip fractures and 76.5% occurred in women. Age-standardized hip fractures rate per 100,000 person-years decreased both in women (-8.7%; from 789.9 in 2007 to 721.5 in 2017) and in men (-4.3%; from 423.9 to 405.6), while the rate of distal femoral fractures increased by 23.9% in women (from 67.78 to 83.95) and 22.7% in men (from 27.76 to 34.06). These changes were associated with an increment in the use of anti-osteoporosis drugs from 2007 to 2011 (from 9.1 to 12.4 DDD/1000 inhabitants/day), followed by a plateau in the period 2012-2017. The use of bisphosphonates increased progressively from 2007 to 2010 (from 8.2 to 10.5 DDD/1000 inhabitants/day), followed by a plateau and then decreased from 2015 onwards. The decreasing trend of hip fractures could be related to a major intake of anti-osteoporosis medications while the increment of distal femoral fractures might be due to population aging and to the use of bisphosphonates and denosumab. Further research is needed to identify and implement interventions to prevent hip and distal femoral fractures.
骨质疏松相关骨折是全球日益严重的公共卫生问题,其给社会和经济带来了巨大负担。本研究旨在评估 2007 年至 2017 年意大利髋部和股骨远端骨折发病率以及抗骨质疏松药物使用的变化趋势。意大利国家住院数据库中使用 ICD-9-CM 编码 820.x 和 821.x 识别出髋部和股骨远端骨折患者,国家药物使用观察数据库中检索到抗骨质疏松药物数据。采用 joinpoint 回归分析确定髋部和股骨远端骨折发病率变化趋势的显著年份,估计观察期内的年平均百分比变化。股骨骨折住院患者为 991,059 例,其中 91.4%为髋部骨折,76.5%发生在女性。女性每 10 万人年标准化髋部骨折发生率(789.9 降至 2017 年的 721.5)和男性(423.9 降至 405.6)均呈下降趋势,而女性远端股骨骨折发生率增加 23.9%(从 67.78 升至 83.95),男性增加 22.7%(从 27.76 升至 34.06)。这些变化与抗骨质疏松药物使用的增加有关,从 2007 年至 2011 年(从 9.1 升至 12.4 DDD/1000 居民/天),随后在 2012 年至 2017 年期间趋于平稳。双膦酸盐的使用从 2007 年至 2010 年逐渐增加(从 8.2 升至 10.5 DDD/1000 居民/天),随后趋于平稳,从 2015 年开始下降。髋部骨折的下降趋势可能与抗骨质疏松药物的大量使用有关,而股骨远端骨折的增加可能与人口老龄化以及双膦酸盐和地舒单抗的使用有关。需要进一步研究以确定和实施预防髋部和股骨远端骨折的干预措施。